
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.63 | 25.9968102073 | 6.27 | 7.9 | 6.02 | 27704 | 7.05422994 | CS |
4 | -0.57 | -6.72963400236 | 8.47 | 8.61 | 6.02 | 26179 | 7.30078579 | CS |
12 | -1.9 | -19.387755102 | 9.8 | 11.1261 | 6.02 | 39583 | 7.92828583 | CS |
26 | -0.48 | -5.72792362768 | 8.38 | 11.1261 | 5.51 | 45151 | 8.07305786 | CS |
52 | 2.9 | 58 | 5 | 11.1261 | 5 | 25197 | 8.10560087 | CS |
156 | 2.9 | 58 | 5 | 11.1261 | 5 | 8365 | 8.10560087 | CS |
260 | 2.9 | 58 | 5 | 11.1261 | 5 | 5642 | 8.10560087 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions